Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Pain

Treatments: Drug: AZD1704

Study type: Interventional

Funder types: Industry

Identifiers

NCT00692042

D0980C00001

Details and patient eligibility

About

The primary aim for this study is to investigate the safety and tolerability of the AZD1704, first time in man.

Enrollment: 80 patients

Sex: All

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers, man or woman of non child-bearing potential
• Provision of signed informed consent.

Exclusion criteria

• History of somatic disease/condition that may interfere with the objectives ot the study, as judged by the Investigator. History of seizures, with the exception of single occasions fever induced seizures in childhood.
• History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the DSM of Mental Disorder, 4th edition
• History of use of antipsychotic, antidepressant or anxiolytic drugs for the treatment of psychiatric disease or symptoms, prescribed as well as non-prescribed use.

Trial design

80 participants in 1 patient group

1

Experimental group

Treatment:

Drug: AZD1704